Phase I Trial of Temozolomide Plus <i>O</i>⁶-Benzylguanine for Patients With Recurrent or Progressive Malignant Glioma

Abstract

Purpose We conducted a two-phase clinical trial in patients with progressive malignant glioma (MG). The first phase of this trial was designed to determine the dose of O 6 -BG effective in producing complete depletion of tumor AGT activity for 48 hours. The second phase of the trial was designed to define the maximum tolerated dose (MTD) of a single dose of temozolomide when combined with O 6 -BG. In addition, plasma concentrations of O 6 -BG and O 6 -benzyl-8-oxoguanine were evaluated after O 6 -BG. Patients and Methods For our first phase of the clinical trial, patients were scheduled to undergo craniotomy for AGT determination after receiving a 1-hour O 6 -BG infusion at 120 mg/m 2 followed by a continuous infusion at an initial dose of 30 mg/m 2 /d for 48 hours. The dose of the continuous infusion of O 6 -BG escalated until tumor AGT was depleted. Once the O 6 -BG dose was established a separate group of patients was enrolled in the second phase of clinical trial, in which temozolomide, administered as a single dose at the end of the 1-hour O 6 -BG infusion, was escalated until the MTD was determined. Results The O 6 -BG dose found to be effective in depleting tumor AGT activity at 48 hours was an IV bolus of 120 mg/m 2 over 1 hour followed by a continuous infusion of 30 mg/m 2 /d for 48 hours. On enrolling 38 patients in six dose levels of temozolomide, the MTD was established at 472 mg/m 2 with dose-limiting toxicities limited to myelosuppression. Conclusion This study provides the foundation for a phase II trial of O 6 -BG plus temozolomide in temozolomide-resistant MG.

Keywords

Affiliated Institutions

• University of Chicago US
• Cancer Research Center US
• National Cancer Institute US

Related Publications